Speaking at AAPS 2010 in New Orleans, Robert Harris, MP’s director of early development, told Outsourcing-pharma that recognition of this need was the main motivation for the firm’s recent move into the early-phase development space.
Harris went on to highlight solubility as one of the major hurdles that developers face when trying to move pre-clinical candidates into trials, particularly with the industry’s focus on large molecule and complex biologic drugs.
“The main issue for a company developing a new drug is the speed with which it can be taken to clinic. Time is of the essence.”
These thoughts echo comments by CEO Nikin Patel, who said: “ [The firm is] committed to bringing innovative scientific approaches to the rapid and pragmatic cost-effective development of formulations for phase I and beyond.”